Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB

Generali Investments Management Co LLC boosted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 408.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,970 shares of the biotechnology company’s stock after acquiring an additional 8,008 shares during the period. Generali Investments Management Co LLC’s holdings in Biogen were worth $1,397,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the 2nd quarter valued at $25,000. Rothschild Investment LLC raised its holdings in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the period. NewSquare Capital LLC raised its holdings in Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 140 shares during the period. WFA of San Diego LLC purchased a new position in shares of Biogen in the second quarter valued at about $32,000. Finally, True Wealth Design LLC boosted its stake in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Performance

Shares of NASDAQ:BIIB opened at $188.02 on Friday. The firm has a fifty day simple moving average of $181.64 and a two-hundred day simple moving average of $162.83. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $27.59 billion, a P/E ratio of 21.34, a PEG ratio of 1.51 and a beta of 0.16. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter last year, the firm earned $3.44 EPS. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on BIIB shares. Mizuho lifted their target price on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Robert W. Baird cut their price objective on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Jefferies Financial Group lifted their price objective on shares of Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, November 28th. Morgan Stanley set a $190.00 target price on shares of Biogen in a research report on Sunday, February 8th. Finally, Stifel Nicolaus raised their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Biogen has an average rating of “Hold” and an average price target of $205.04.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.